and c-KIT is thought to cause dose-limiting myelosuppression. Through a rational design approach, novel FLT3 inhibitors were synthesized employing a pyridine/pyrimidine warhead. The most potent compound identified from the studies is compound 13a, which exhibited an IC 50 value of 13.9 ± 6.5 nM against the FLT3 kinase with high selectivity over c-KIT. Mechanism of action studies suggested that 13a is a Type-II kinase inhibitor, which was also supported through computer aided drug discovery (CADD) efforts. Cell-based assays identified that 13a was potent on a variety of FLT3-driven cell lines with clinical relevance. We report herein the discovery and therapeutic evaluation of 4,6-diamino pyrimidine-based Type-II FLT3 inhibitors, which can serve as a FLT3-selective scaffold for further clinical development.
FLT3 inhibition. All synthesized compounds were screened for inhibition of the FLT3 kinase. The initial screening was performed at a single point concentration of 20 µM to determine preliminary activity. After, IC 50 Design strategy for novel FLT3 inhibitors. The basic heterocycle in blue was designed to exploit the hinge region, while the C-region heterocycle was designed to access the allosteric pocket. At the basic pharmacophore region, free rotation was engineered into the scaffold to help improve FLT3 selectivity. Design strategies were implemented through CADD and rational design efforts in the SAR discussion.
SCientiFiC REPORtS | (2018) 8:3722 | DOI:10.1038/s41598-018-21839-3 values were determined for all active compounds. FLT3 inhibition and LE (ligand efficiency) values for the pyrimidine series are provided in Tables 1-3 . Table 1 contains the data for the pyrimidine series of compounds 13a-13j, wherein the other terminal of the scaffold comprises a pyrazole ring. Table 2 contains the data for pyrimidine series of compounds 13k-13q, wherein the other terminal of the scaffold comprises an isoxazole ring. Table 3 contains the data for pyrimidine series of compounds 13r-13ak, wherein the other terminal of the scaffold comprises a phenyl ring. Pyridine-based compound 18 showed inhibition of the FLT3 kinase with an IC 50 value of 5719 nM.
Amongst all compounds tested, the pyrimidine series of compounds, wherein the other terminal comprises a pyrazole ring, exhibited promising FLT3 inhibition with IC 50 values in the lower nanomolar range ( Table 1) . The most potent compound, 13a, displayed inhibition of the FLT3 kinase with an IC 50 value of 13.9 nM. Interestingly, the urea analog (compound 24a) of compound 13a, exhibited an IC 50 value of 41 nM against the FLT3 kinase. This suggests that free rotation at the kinase bridge region could be an important factor for potent inhibition.
Kinase selectivity. FLT3 inhibitors 13a and 13k were further studied for effects on other kinases in the greater kinome (Table 4 ). Compound 13a exhibited weak inhibition of CSF-1R, RET, and Aurora B with IC 50 values of 13 µM, 4.17 µM, and 79.83% inhibition at 20.0 µM, respectively. Compound 13a displayed excellent activity for the activation loop mutation, FLT3 D835Y , with an IC 50 value of 72.5 nM. At the enzymatic level, compound 13a is very selective for the FLT3 kinase with >100 fold less inhibition on other closely related kinases. Importantly, compound 13a has >500 fold selectivity for FLT3 over c-KIT (Fig. 6 ). This selectivity could help reduce the incidence of toxicity as concomitant blockade of FLT3 and c-KIT has been shown to cause myelosuppression 28 . Interestingly, the only difference between 13a and 13k is ring C (the basic pharmacophore is depicted in Fig. 2 ). In the case of 13a, ring C is a pyrazole while in 13k it is an isoxazole. Therefore, it appears that FLT3 prefers pyrazole functionality at the R 2 position. In another pair 13 f (IC 50 = 961 nM) versus 13 l (IC 50 = 567 nM), where the R 1 substituent is 3-CF 3 phenyl and ring C is either pyrazole or isoxazole, the trend of FLT3 inhibition was found to be opposite. Cell Based Studies. Compounds were progressed to cell-based studies to further evaluate their therapeutic utility. Three FLT3-driven cell line models were utilized for the studies: FLT3-driven Ba/F3 cells, Molm 14 cells with various FLT3 mutations, and MV4-11 AML cells. As can be seen from the data in Table 5 , compound 13a exhibited potent inhibitory activity against Ba/F3 FLT3-ITD, Molm14 par, and MV4-11 cells. However, despite having in vitro inhibitory activity against the FLT3 D835Y mutation, compound 13a displayed a ~10-fold reduction in cellular activity against the Molm14 D835Y cell line. Compound 13a also displayed a ~10-fold reduction against the Molm14 F691L cell line, which harbors a "gatekeeper" mutation. Therefore, 13a is a potent and selective inhibitor of FLT3-ITD but exhibits a moderate reduction in activity against FLT3-ITD harboring secondary kinase domain mutations in cell-based studies. Other inhibitors screened, such as compound 13d, exhibited good FLT3 inhibition but failed to effectively inhibit FLT3-driven cellular growth. This can be attributed to the high polarity of 13d in which the compound has difficulty diffusing through the cellular membrane. Compound 13k exhibited the greatest overall potency against FLT3-driven Ba/F3 and MV4-11 cells. Based on in vitro enzymatic screening, this result was expected as compound 13k had very weak inhibition against the FLT3 D835Y mutant kinase.
Computational Studies. To further understand ligand/receptor binding interactions, 13a, 13k, and 18 were computationally modeled in the FLT3 tyrosine kinase ( Fig. 7) . In all instances, each compound is predicted to bind to the FLT3 kinase in a Type-II DFG-out fashion. The R2 substituent accesses an allosteric pocket while the R1 substituent is oriented towards the solvent. The pyrimidine heterocycle remains in close proximity to the kinase hinge, forming a hydrogen-bond network. From the enzymatic screening results, compound 13a drastically out-performed compound 18. The difference in activity can be attributed to the ability to form hydrogen bonds at the hinge. As can be seen with compound 13a, the pyrimidine is oriented towards the hinge and forms a hydrogen bond network. However, compound 18 is based on a pyridine scaffold, which is predicted to face away from the hinge. Therefore, 18 is unable to engage in hydrogen-bond interactions at the FLT3 kinase hinge despite having a similar structure to that of 13a.
Employing computational modeling, FLT3 binding interactions were further studied with compound 13a (Fig. 8 ). At the hinge of FLT3, compound 13a is predicted to engage in two hydrogen bonds with CYS694. Both hydrogen bonds occur with the amide backbone of FLT3. Other kinase inhibitors, such as sunitinib (SUTENT®), also engage in two hydrogen bonds at the hinge region. These hydrogen bond networks are essential for activity since compound 18, a compound that cannot readily form hydrogen bonds at the hinge region, is >100 fold less active than 13a. At the solvent region, the methyl sulfone substituent of 13a is predicted to interact with ASN701. It is predicted that this interaction limits the free rotation of 4-(methylsulfonyl)phenyl and helps hold the ring system in place. This stabilization ensures proper hydrogen bonding at the hinge. Compound 13a is able to access the FLT3 allosteric pocket by forming a hydrogen bond with ASP829 from the DFG motif at the bridge region. This interaction stabilizes the DFG motif in the 'out' position and permits the pyrazole moiety of 13a to enter the allosteric pocket. As can be observed from the docking pose of 13a, the methylene linker is rotated relative to the amide bond. It is predicted that this free rotation permits tighter binding since compound 24a, the non-rotatable, urea analog of 13a, exhibited ~3 fold lower activity. Within the allosteric pocket, the pyrazole substituent of 13a efficiently fills the region. Because the isoxazole moiety at R 2 , as observed with compound 13k, is ~5 fold less active than 13a the isoxazole is not supreme in the allosteric pocket. On the pyrazole of 13a there is a methyl, as well as a t-butyl, and it is hypothesized that both of these aliphatic groups are important to efficiently fill the FLT3 allosteric pocket.
Mechanism of Inhibition.
Computational modeling studies suggested that compound 13a bound to the DFG-out conformation of the FLT3 kinase and mechanistic inhibition studies were completed to confirm binding. First, compound 13a was pre-incubated with the FLT3 kinase at various time intervals. Type-II kinase inhibitors display a time-dependent binding interaction, where an increase in incubation causes an increase in compound activity. This is because the compound has to push into the allosteric pocket of the kinase, which causes the inhibitor to have a time dependent k on . As can be seen from the incubation studies, compound 13a had an increase in IC 50 with an increase in pre-incubation ( Fig. 9 ). From no incubation to a 90-minute pre-incubation, the IC 50 value exhibited a statistically significant decrease (p < 0.05). In order for 13a to reach maximal inhibition of the FLT3 kinase, the compound required approximately 60 minutes of pre-incubation. This is highly suggestive that compound 13a is accessing the FLT3 allosteric pocket and is a Type-II kinase inhibitor because the compound exhibits statistically significant, time-dependent activity. In a separate experiment, the IC 50 value of 13a was determined at various concentrations of ATP ( Fig. 9 ). Because 13a is hypothesized to access an allosteric pocket on the FLT3 kinase, the compound was expected to display non-competitive inhibition characteristics and should not be directly competitive with ATP. It was determined that an increase in ATP concentration did not cause a statistically significant increase in FLT3 IC 50 . Therefore, ATP is unable to relieve the FLT3 inhibition induced by 13a because 13a binds to the DFG-out form of the kinase, and the DFG-out conformation does not have affinity for ATP. Therefore, these mechanistic studies are highly suggestive that compound 13a is a Type-II, non-competitive inhibitor that accesses the FLT3 allosteric pocket.
FLT3 vs c-KIT selectivity.
To understand the selectivity of 13a for FLT3 over c-KIT, molecular modeling studies were performed. It was identified that 13a does not form the correct hydrogen bonding network at the hinge of c-KIT. As can be seen in the FLT3 docking structure, 13a forms two hydrogen bonds at CYS694, which is the hinge region. However, in c-KIT, 13a is oriented away from the hinge, and is unable to form essential hydrogen bonds ( Fig. 10 ). This is likely due to how 13a interacts in the allosteric region as the pyrazole moiety is flipped between FLT3 and c-KIT. In fact, the computational binding affinity of 13a for FLT3 was determined to be −14.479 kcal/mol while c-KIT was −8.895 kcal/mol. Therefore, computationally 13a is very selective for FLT3 over c-KIT, which was also confirmed experimentally.
Discussion
Using computational studies, a series of extended compounds comprising pyrimidine as the kinase-hinge warhead connected to two aromatic rings (A and B) via an amine bond were synthesized. Amongst synthesized (Table 3 ) and amongst pyrazole and oxazole, pyrazole is preferred. (3) N-methyl substitution on pyrazole (ring C) is preferred over other bulkier groups (Table 1 ). (4) The linkage of the central heterocycle with ring B via -NH-is preferred over -O-linkage (Tables 1-3 ). (5) Replacement of ring A with a single methyl does not have significant impact on FLT3 inhibitory activity (13a versus 13b) ( Table 1 ). (6) The 3-atom linker between ring B and C can be -CH 2 -CO-NH-or -NH-CO-NH-, which both exhibit a similar level of activity (Tables 1-2 ). (7) It appears that the t-butyl substitution on ring C is essential for efficient interaction of the inhibitor with the allosteric pocket (Tables 1-3 
and Figs 7-8). (8)
The carbonyl group of the 3-atom linker exhibits critical hydrogen bonding interactions with ASP829 of the DFG motif ( Fig. 8 ). Based on these key SAR features, compound 13a was determined to be the best and most potent inhibitor of FLT3. In a cellular growth inhibition assay, compound 13a displayed excellent activity for the activation loop mutation, FLT3 D835Y , with an IC 50 value of 72.5 nM and was found to possess >500 fold selectivity for FLT3 over c-KIT in in vitro kinase assays. The discrepancy between the enzymatic inhibition of FLT3 D835Y and cellular inhibition of Molm14 D835Y is likely because Molm14 D835Y cells express a FLT3 double mutant 29 . Molm14 D835Y cells contain an internal tandem duplication (ITD) and the D835Y point mutation in the FLT3 kinase. Kinase double mutations are notoriously more difficult to inhibit 29, 30 , while the biochemical assay only contains the kinase domain with a single, D835Y point mutation. In computational studies, compound 13a was found to enter the allosteric pocket, which was further confirmed by time-dependent enzyme kinetic studies. Compound 13a had an increase in IC 50 with an increase in pre-incubation, which is suggesting that the compound is accessing the FLT3 allosteric pocket and is a Type-II kinase inhibitor. Furthermore, the selectivity of compound 13a towards FLT3 over c-KIT was studied using molecular modeling and was then experimentally demonstrated.
In conclusion, the rational design of a series of 4,6-diamino pyrimidnyl compounds led to the discovery of a potent and selective FLT3 kinase inhibitor 13a. Compound 13a achieved a FLT3 IC 50 value of 13.9 nM and was active against FLT3-driven cell lines. 13a was also active on the FLT3 D835Y mutant with an IC 50 of 72.5 nM and displayed activity in FLT3 cell lines with GI 50 between 0.009-2.0 µM. From these studies, it was determined that the allosteric pocket of FLT3 is more responsive to pyrazole when compared to isoxazole. Further, from computational modeling, it was identified that amino acid ASN701 can interact with 13a, which can aid in the design of future FLT3 inhibitors. Mechanistic inhibition studies suggested that 13a is a Type-II, non-competitive inhibitor that accesses the FLT3 allosteric pocket. 13a was also found to be highly selective for FLT3 over c-KIT, which can aid in the discovery of second-generation FLT3 inhibitors with attenuated myelosuppressive profiles. Currently, further modification of lead 13a is underway to enhance activity on activation loop and gatekeeper mutations.
Methods
General. All solvents were reagent grade or HPLC grade and all starting materials were obtained from commercial sources and used without further purification. Purity of final compounds was assessed using a Thermo Finnigan LCQ Deca with Thermo Surveyor LCMS System at variable wavelengths of 254 nm and 214 nm and final compound purity was >95%. The HPLC mobile phase consisted of a water-methanol gradient buffered with 0.1% formic acid. 1 H NMR spectra were recorded at 400 MHz and 13 C spectra were recorded at 100 MHz, both completed on a Varian 400 MHz instrument (Model# 4001S41ASP). High-resolution mass spectrometry was completed using a Bruker 9.4 T Apex-Qh hybrid Fourier transfer ion-cyclotron resonance (FT-ICR) mass spectrometer. Compound activity was determined with the EZ Reader II plate reader (PerkinElmer®, Walthman, USA). All compounds were purified using Silica gel (0.035-0.070 mm, 60 Å) flash chromatography, unless otherwise noted. Microwave assisted reactions were completed in sealed vessels using a Biotage Initiator microwave synthesizer. Synthesis of ethyl 2-(4-(6-chloropyrimidin-4-yl)amino)phenyl)acetate (7) . To the mixture of ethyl 4-aminophenyl acetate 5 (20 g, 111.60 mmol) and 4,6-dichloropyrimidine 6 (13.79 g, 92.56 mmol) in EtOH (200 mL) was added triethyl amine (17.80 g, 176.23 mmol) The reaction mixture was stirred at 80 °C for 12 h. After completion of reaction as indicated by TLC, the solvent was removed under reduced pressure. The crude product thus obtained was purified by silica gel (100-200 mesh) flash chromatography with hexanes/EtOAc (1:3) to afford 7 as white solid (26.50 Synthesis of ethyl 2-(4-(6-(4-methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)acetate (10). The 4-(methylsulfonyl)benzenamine 8a (0.882 g, 5.5 mmol) and Cs 2 CO 3 (2.79 g, 8.58 mmol) were added to the solution of compound 7 (1 g, 3.4 mmol) in dioxane (4 ml). The reaction mixture was then degassed with argon. After 5 minutes, Pd(PPh 3 ) 4 (0.118 g, 0.102 mmol) was added and the reaction mixture was allowed to stir at 110 °C for 12 h. After completion of the reaction as indicated by TLC, the solvent was removed under reduced pressure. The reaction was slowly basified with aqueous NaHCO 3 and the obtained aqueous layer was extracted with ethyl acetate (100 mL × 3). The organic phase was washed with aqueous NaHCO 3 (100 mL 13 2-(4-(6-(3-(Pyrrolidin-1-yl)propylamino)pyrimidin-4-ylamino)phenyl)-N-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl) acetamide (13d). Sticky pale yellow solid (0.039 g, 28.26%); 1 13 13 13 13 [1, 4] 25, 151.95, 145.97, 137.04, 132.47, 131.95, 130.73, 129.24, 129.12, 125.73, 121.77, 119.30, 85.70, 43.01, 42.12, 34.41, 31. 13 13 13 (20) . To the mixture of tert-butyl 4-aminophenylcarbamate 19 (2.09 g, 10.06 mmol) and 4,6-dichloropyrimidine 6 (1 g, 6.71 mmol) in EtOH (20 mL) was added triethyl amine (1.17 g, 11.58 mmol) The reaction mixture was stirred at 80 °C for 12 h. After completion of reaction as indicate by TLC, the solvent was removed under reduced pressure. The crude product thus obtained was purified by silica gel (mesh 100-200) flash chromatography with hexanes/EtOAc (1:3) to afford 20 as a white solid (2.85 g, 89.06%); m.p. 155-157 °C; 1 
2-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-yloxy)phenyl)-N-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl

2-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)-N-(3-tert-butyl-1-(4-fluorophenyl)-1H-pyrazol-5-yl)acetamide (13g
2-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)-N-(3-tert-butyl-1-p-tolyl-1H
2-(4-(6-Morpholinopyrimidin-4-ylamino)phenyl)-N-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)acetamide
2-(4-(6-(4-Methylpiperazin-1-yl)pyrimidin-4-ylamino)phenyl)-N-(3-tert-butyl-1-(4-bromophenyl)-1H-pyrazol
2-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)-N-(5-tert-butylisoxazol-3-yl)acetamide (13k
2-(4-(6-(3-(Trifluoromethyl)phenylamino)pyrimidin-4-yloxy)phenyl)-N-(5-tert-butylisoxazol-3-yl)acetamide
2-(4-(6-(3-(Pyrrolidin-1-yl)propylamino)pyrimidin-4-ylamino)phenyl)-N-(5-tert-butylisoxazol-3-yl)acetamide (13n
2-(4-(6-(3-(Pyrrolidin-1-yl)propylamino)pyrimidin-4-ylamino)phenyl)-N-(4-(trifluoromethoxy)phenyl)acetamide
2-(4-(6-(2,3-Dihydrobenzo[b]
Synthesis of tert-butyl 4-(6-chloropyrimidin-4-ylamino)phenylcarbamate
Synthesis of tert-butyl 4-(6-(4-(methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenylcarbamate (21)
. The 4-(methylsulfonyl)benzenamine 8a (0.802 g, 4.68 mmol) and Cs 2 CO 3 (2.53 g, 7.78 mmol) were added to the solution of compound 20 (1 g, 3.12 mmol) in dioxane (4 ml). The reaction mixture was then degassed with argon. After completion of 5 minutes, Pd(PPh 3 ) 4 (0.108 g, 0.093 mmol) was added and the reaction mixture was allowed to stirr at 110 °C for 12 h. After completion of reaction as indicated by TLC, the solvent was removed under reduced pressure. The obtained residue was slowly basified with aqueous NaHCO 3 and extracted with ethyl acetate (100 mL × 3). The organic layer was washed with aqueous NaHCO 3 (100 mL × 3) followed by brine (100 mL × 3) solution. The obtained organic layer was dried over MgSO 4 , and solvent was evaporated to yield 21 as a yellow solid (0.950 g, 66.90%). m.p. 178-180 °C; 1 H NMR (400 MHz, DMSO-d 6 ): δ 9.61 (s, 1H), 9.21 (s, 1H), 9.08 (s, 1H), 8.28 (s, 1H), 7.83 (d, J = 8.0Hz, 2H), 7.74 (d, J = 12.0Hz, 2H), 7.38-7.32 (m, 4H), 6.12 (s, 1H), 3.10 (s, 3H), 1.43 (s, 9H); 13 as follows: 1) All hydrogens were added as 'Polar Only' 2) A grid box for the ATP binding site was created. Compounds to be computationally modeled were assigned appropriate rotatable bonds using AutoDock Tools. To computationally model the compounds, AutoDock Vina was employed. AutoDock Vina provides docking scores in terms of ΔG values. After the modeling study, kinase inhibitors docked in FLT3 were visualized and analyzed with Discovery Studio 3.5.
Cell Cultures. Stable BaF3 populations expressing activated FLT3 were generated by retroviral spinfection with the appropriate mutated plasmid followed by selection and growth factor withdrawal as previously described 34 . The BaF3 cell line was originally obtained from the laboratory of Charles Sawyers and has not been authenticated. MV411 and Molm14 cells were obtained from the laboratory of Scott Kogan and authenticated by Promega STR analysis in June 2013. All cell lines were mycoplasma-free. Cells were incubated with compounds for 48 hours and proliferation was assessed using CellTiter-Glo (Promega; Madison, WI) according to the manufacturer's recommendation on a SpectraMax M3 microplate reader using SpectraMax Software (Molecular Devices; Sunnyvale, CA). All cell viability data shown is reflective of experiments performed a minimum of three times.
